ETS Wound Care said today it won FDA clearance for its Mirragen advanced wound matrix with indications for treating acute and chronic wounds.
The Mirragen matrix is a fully resorbable borate glass matrix composed of fibers and beads which the Rolla, Mo.-based company claims is highly effective in wound care management.
“Anyone who is treating or experiencing discomfort from acute or chronic wounds will immediately recognize the benefits of Mirragen. Mirragen has the potential to reduce the required number of episodes and duration of wound care treatment, while allowing the body to effectively heal a variety of wounds, both acute and chronic,” Peggy Earl of the Phelps County Regional Medical Center said in a prepared statement.
ETS Wound Solutions’ Mirragen is designed to be packed into wounds to manage and control wound fluids while the resorbable matrix creates an appropriate environment for wound healing, the company said.
“The recent FDA approval is a significant milestone for ETS. ETS Wound Care is pioneering an entirely new therapeutic option for wound care. The Mirragen Advanced Wound Matrix is the first product utilizing our innovative borate fiber technology engineered to improve patient outcomes,” prez & CEO Chad Lewis said in a press release.
The company said it is aiming for a commercial launch of Mirragen early in the 2nd quarter of this year, with broader availability in the domestic market in 2018.